• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂质组学、微生物群与肠道感染结果

Lipidomics, Microbiota, and Intestinal Infection Outcome.

作者信息

Branković Marija, Kraišnik Marija, Zdravković Dimitrije, Kraišnik Nemanja, Jelić Filip, Nikolić Novica, Đurašević Siniša, Tosti Tomislav, Gmizić Tijana, Todorović Zoran

机构信息

University Hospital Medical Center Bežanijska kosa, 11000 Belgrade, Serbia.

Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

出版信息

Int J Mol Sci. 2025 Aug 24;26(17):8214. doi: 10.3390/ijms26178214.

DOI:10.3390/ijms26178214
PMID:40943140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12428561/
Abstract

It is mostly known which microorganisms make up the intestinal microbiota and what their role is in the digestive tract. Moreover, there is evidence about the influence of these microorganisms, especially bacteria, on the functioning of the human body in general. Intestinal microbiota is metabolically active and synthesizes numerous molecules that are an important part of biochemical processes in the human body, as well as signaling pathways. Some of these molecules are of lipid origin, which is why new knowledge in the field of lipidomics can help in their more precise identification. It is now clear that the lipid profile of the stool depends on the composition and metabolic activity of the microbiota. Therefore, under changed conditions, such as the existence of an infection, there are changes in the lipid profile of the stool. One of the epidemiologically most important and most studied infections of the digestive tract is infection. This infection is recurrent in a large number of cases; it is related to resistance to antibiotics and their irrational use, and because of that, further research in this area would bring insight into possibly new knowledge that would help in more effective suppression of this infection.

摘要

人们大多已经知道构成肠道微生物群的是哪些微生物,以及它们在消化道中的作用是什么。此外,有证据表明这些微生物,尤其是细菌,总体上对人体功能有影响。肠道微生物群具有代谢活性,能合成众多分子,这些分子是人体生化过程以及信号通路的重要组成部分。其中一些分子源自脂质,这就是脂质组学领域的新知识有助于更精确鉴定它们的原因。现在很清楚,粪便的脂质谱取决于微生物群的组成和代谢活性。因此,在诸如感染存在等变化的条件下,粪便的脂质谱会发生变化。消化道在流行病学上最重要且研究最多的感染之一是[此处原文未明确感染名称]感染。这种感染在大量病例中会复发;它与对抗生素的耐药性及其不合理使用有关,正因为如此,该领域的进一步研究将带来可能有助于更有效抑制这种感染的新知识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca79/12428561/581cc38cf02a/ijms-26-08214-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca79/12428561/f69ccadf39f5/ijms-26-08214-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca79/12428561/b8b5e6449b6f/ijms-26-08214-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca79/12428561/7b768cbde525/ijms-26-08214-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca79/12428561/581cc38cf02a/ijms-26-08214-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca79/12428561/f69ccadf39f5/ijms-26-08214-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca79/12428561/b8b5e6449b6f/ijms-26-08214-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca79/12428561/7b768cbde525/ijms-26-08214-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca79/12428561/581cc38cf02a/ijms-26-08214-g004.jpg

相似文献

1
Lipidomics, Microbiota, and Intestinal Infection Outcome.脂质组学、微生物群与肠道感染结果
Int J Mol Sci. 2025 Aug 24;26(17):8214. doi: 10.3390/ijms26178214.
2
Aspects of Genetic Diversity, Host Specificity and Public Health Significance of Single-Celled Intestinal Parasites Commonly Observed in Humans and Mostly Referred to as 'Non-Pathogenic'.人类常见且大多被称为“非致病性”的单细胞肠道寄生虫的遗传多样性、宿主特异性及公共卫生意义
APMIS. 2025 Sep;133(9):e70036. doi: 10.1111/apm.70036.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).粪便微生物移植治疗复发性艰难梭菌(艰难梭菌)。
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.
5
Differential modulation of post-antibiotic colonization resistance to by two probiotic strains.两种益生菌菌株对抗生素后定植抗性的差异调节
mBio. 2025 Jul 21:e0146825. doi: 10.1128/mbio.01468-25.
6
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
7
Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children.用于预防成人和儿童艰难梭菌相关性腹泻的益生菌。
Cochrane Database Syst Rev. 2025 Sep 11;9(9):CD006095. doi: 10.1002/14651858.CD006095.pub5.
8
Fecal microbiota live - jslm (Rebyota™/RBL) for management of recurrent infection.用于治疗复发性感染的粪便微生物群活菌制剂-jslm(Rebyota™/RBL)
Future Microbiol. 2024;19(14):1243-1251. doi: 10.1080/17460913.2024.2364583. Epub 2024 Jul 11.
9
Host origin of microbiota drives functional recovery and clearance in mice.微生物群的宿主来源驱动小鼠的功能恢复和清除。
mBio. 2025 Jun 2:e0110825. doi: 10.1128/mbio.01108-25.
10
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.

本文引用的文献

1
Activity of GPCR-targeted drugs influenced by human gut microbiota metabolism.人肠道微生物群代谢对G蛋白偶联受体靶向药物活性的影响。
Nat Chem. 2025 Apr 3. doi: 10.1038/s41557-025-01789-w.
2
Gut microbiome and plasma lipidome analysis reveals a specific impact of infection on intestinal bacterial communities and sterol metabolism.肠道微生物组和血浆脂质组分析揭示了 感染对肠道细菌群落和固醇代谢的特定影响。
mBio. 2024 Oct 16;15(10):e0134724. doi: 10.1128/mbio.01347-24. Epub 2024 Aug 27.
3
AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases.
AGA 临床实践指南:基于粪便微生物群的疗法治疗特定胃肠道疾病。
Gastroenterology. 2024 Mar;166(3):409-434. doi: 10.1053/j.gastro.2024.01.008.
4
Collaborative Metabolism: Gut Microbes Play a Key Role in Canine and Feline Bile Acid Metabolism.协同代谢:肠道微生物在犬猫胆汁酸代谢中起关键作用。
Vet Sci. 2024 Feb 18;11(2):94. doi: 10.3390/vetsci11020094.
5
Another renaissance for bile acid gastrointestinal microbiology.胆汁酸胃肠微生物学的另一个复兴。
Nat Rev Gastroenterol Hepatol. 2024 May;21(5):348-364. doi: 10.1038/s41575-024-00896-2. Epub 2024 Feb 21.
6
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk.治疗代谢功能障碍相关脂肪性肝病(MASLD)及心血管风险增加患者的新治疗方法
Diagnostics (Basel). 2024 Jan 22;14(2):229. doi: 10.3390/diagnostics14020229.
7
Loss of bile acid-altering enzymes impacts bacterial fitness and the global metabolic transcriptome.胆汁酸修饰酶的缺失影响细菌的适应性和全球代谢转录组。
Microbiol Spectr. 2024 Jan 11;12(1):e0357623. doi: 10.1128/spectrum.03576-23. Epub 2023 Nov 29.
8
Ceramides and their roles in programmed cell death.神经酰胺及其在细胞程序性死亡中的作用。
Adv Med Sci. 2023 Sep;68(2):417-425. doi: 10.1016/j.advms.2023.10.004. Epub 2023 Oct 20.
9
The microbial-derived bile acid lithocholate and its epimers inhibit growth and pathogenicity while sparing members of the gut microbiota.微生物衍生的胆汁酸石胆酸及其差向异构体抑制 生长和致病性,同时不影响肠道微生物群的成员。
J Bacteriol. 2023 Sep 26;205(9):e0018023. doi: 10.1128/jb.00180-23. Epub 2023 Sep 11.
10
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).粪便微生物移植治疗复发性艰难梭菌(艰难梭菌)。
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.